Rehmann Capital Advisory Group’s Aimmune Therapeutics AIMT Stock Holding History

Rehmann Capital Advisory Group’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$2.41K	Buy	+115	New	+$2.35K	﹤0.01%	1383
2018 Q4	–	Sell	-242	Closed	-$6.6K	–	2207
2018 Q3	$6.6K	Sell	242 -34	-12%	-$962	﹤0.01%	1495
2018 Q2	$7.42K	Buy	276 +34	+14%	+$1.04K	﹤0.01%	1443
2018 Q1	$8K	Buy	+242	New	+$8.52K	﹤0.01%	1399

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rehmann Capital Advisory Group's AIMT Position: Q3 2019 in Review

Rehmann Capital Advisory Group opened a new position in Aimmune Therapeutics (AIMT) in Q3 2019: 115 shares worth $2.41K. The stake represents ﹤0.01% of the portfolio and ranks #1383 among its holdings. This is a return to the name: Rehmann Capital Advisory Group previously reported a position in AIMT as recently as Q3 2018.

Rehmann Capital Advisory Group first reported a position in AIMT in Q1 2018 and has held it in 4 quarters since. The position peaked at $8K in Q1 2018. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

Rehmann Capital Advisory Group held 115 shares of Aimmune Therapeutics worth $2.41K as of Q3 2019.
Aimmune Therapeutics was a new Rehmann Capital Advisory Group position in Q3 2019.
Aimmune Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1383 holding.
Rehmann Capital Advisory Group first reported a position in Aimmune Therapeutics in Q1 2018 and has held it in 4 quarters since.
Rehmann Capital Advisory Group's Aimmune Therapeutics position peaked at $8K in Q1 2018.
146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.